Prostate Cancer Treatment in a Virus?
Reported March 10, 2010
(Ivanhoe Newswire) — A common respiratory virus, called a reovirus, may provide a new, safe approach to treating prostate cancer.
The reovirus is a non-attenuated, environmental virus that has oncolytic potential — the ability to cause cancer cell death — against many types of cancer, specifically lymphoid, ovarian, breast, pancreatic and high grade glioma cancer, according to a new study. This is the first time the virus has been studied in the area of prostate cancer.
“The reovirus is a very common, ubiquitous virus that most people are exposed to,” Don Morris, M.D., Ph.D., medical oncologist in the Department of Oncology at the Tom Baker Cancer Center in Alberta, Canada, was quoted as saying. “As far as we know, it doesn’t cause any significant illness in humans, even though when someone is exposed to it, it manifests, at most, as a mild respiratory infection or mild diarrhea. For the treatment of localized prostate cancer, we found that the reovirus is safe and has evidence of specific tumor vs. normal prostate cell efficacy.”
Dr. Morris and colleagues examined the efficacy of the reovirus as an experimental therapeutic for prostate cancer in vitro and in vivo. Among the six patients who participated in the study, all had early-stage, organ-confined prostate cancer. Each patient underwent a single intralesional virus injection into a suitable prostate cancer nodule via transrectal ultrasound guidance. Three weeks later, Dr. Morris and his team removed the prostate as part of the patient’s standard treatment for correlative science analysis.
Findings showed safety and efficacy with minimal toxicity and no viral replication in the normal parts of the prostate, according to Dr. Morris. Cancer cell death was evident in the prostate. Studies to date have suggested that the virus’ side effects are relatively modest, consisting of mild, self-limiting, flu-like symptoms.
“Our results are a stepping stone into future prostate cancer clinical trials with another category of cancer therapeutics,” said Dr. Morris.
Robert Clarke, Ph.D., D.Sc., professor of oncology at Lombardi Comprehensive Cancer Center at Georgetown University, agreed, stating that he believes this study is worthy of subsequent clinical trials of the reovirus as a possible way of treating some prostate cancers.
“People have known of this application of the reovirus in trials, but no one to my knowledge has conducted studies in prostate cancer,” Dr. Clarke was quoted as saying. “I think this is an interesting approach. There is not a lot done in oncolytics, but clearly it is an area that is getting increasing attention, and we need everything we can get our hands on to make a difference in these patients.”
SOURCE: Cancer Research, March 9, 2010
